Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201609-02 Development of telomerase derived peptide GV1001, in Alzheimer Disease(CNS Diseases, Protein) [02.28.2017]


Development and Market Objectives

- Alzheimer’s disease (AD), the leading cause of dementia worldwide, is characterized by aggregation and accumulation of specific proteins such as amyloid beta and tau, resulting in neurotoxicity, damage to mutual communications of neurons or glial cells, neuroinflammation, neuronal cell death, which contribute to the dysfunction and decrease in numbers of neuronal cells. 

- This project focuses on the development of novel Alzheimer’s disease therapeutic drug through validation of therapeutic efficacy and mechanism of action of GV1001 using in vitro cellular model and transgenic mouse model, overcoming the limit of conventional AD drug and regulating various mechanism of action simultaneously.  

Unmet Medical Need & Target Patients

- According to the report from Alzheimer’s Disease International, an international federation of Alzheimer’s Associations of 76 countries, the number of AD patients worldwide was estimated to be 44 million in 2013, 76 million in 2030, and 135 million in 2050.

- Until now, the precise mechanism of Alzheimer's disease has not been clarified. Due to the nature of the disease, AD has a very complicated pathogenesis, making it difficult to develop treatment methods.

- Currently, AD drugs used in clinic are known to have the effect of mitigating the symptoms and delaying the progression of AD. However, these drugs are not disease-modifying drugs and their therapeutic efficacy is negligible

- Therefore, the development of the novel and effective drug with new concept is urgently needed.


- Validation of therapeutic efficacy of GV1001 using in vitro cellular model and transgenic mouse model of AD. 
- Study on the mechanism of action of GV1001 in various in vitro models. 
- ADME study    

Intellectual Property

- Substance patent and patent application and registration for new usage
- Expansion of patent portfolios when acquiring additional data 

Competitive Advantages

- A new first-in-class peptide drug that overcomes the side effects and low efficacy of existing drugs.
- Abundant multinational overseas clinical experience for about 15 years.
- Promoting comprehensive license agreements based on clinical data and possibilities for various indications as well as Alzheimer's disease
- Possessing a patent portfolio with numerous patents and superior technological competitiveness



Research Period

Feb. 1, 2017 ~ Jan. 31, 2018


GemVax & KAEL Co.,Ltd

Developmental Stage


Additional Information

Contact Information

Address Company Name: GemVax & KAEL Co.,Ltd
WebSite Homepage: Contact Person: Eujin Hyun
E-mail: Contact: +82-70-8670-0943

Related Projects

Related Project